Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

GLP-1 drugs may help patients shed regained weight after bariatric surgery (opens in a new tab)

medicalxpress.com · 2026-10-29

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 5 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All five claims match what the study reports.

  • 5 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5SupportedPeople who regain weight after bariatric surgery may benefit from glucagon-like peptide-1 receptor agonists (GLP-1 medications).View evidenceHide evidence

Why this verdict

The abstract-level profile reports an observational cohort in which GLP-1 receptor agonist users with post-bariatric weight recurrence lost a larger percentage of recurrent weight at 6 and 12 months than matched non-users. The story’s headline wording is hedged as 'may benefit,' so it does not overstate the observational evidence as proven causation.

1

Study evidence

At 6 months, GLP-1 RA users lost a larger proportion of recurrent weight than matched non-users.Mean % recurrent weight lost: 9.6% (GLP-1 RA users) vs. 4.3% (non-users); p = 0.005

“We conducted a retrospective new-user cohort study using OneFlorida+ Data Trust (2015-2024) among adults with ≥ 10% post-MBS weight recurrence.”
Claim 2 of 5SupportedThe study found that patients prescribed these medications lost more of their regained weight over six and 12 months than comparable patients who did not use them.View evidenceHide evidence

As statedmore of their regained weight over six and 12 months

Why this verdict

The paper profile states that GLP-1 RA initiators were compared with matched non-users, with IPTW used for confounding control, and that users lost a larger share of recurrent weight at both 6 and 12 months. The story frames this as a study finding among comparable patients rather than a causal conclusion.

1

Study evidence

At 6 months, GLP-1 RA users lost a larger proportion of recurrent weight than matched non-users.Mean % recurrent weight lost: 9.6% (GLP-1 RA users) vs. 4.3% (non-users); p = 0.005

“We conducted a retrospective new-user cohort study using OneFlorida+ Data Trust (2015-2024) among adults with ≥ 10% post-MBS weight recurrence.”
Claim 3 of 5SupportedAt six months, patients using GLP-1 medications lost an average of 9.6% of their regained weight, compared with 4.3% among nonusers; at 12 months, the corresponding figures were 14.8% and 8.1%.View evidenceHide evidence

As stated9.6% vs 4.3% at six months; 14.8% vs 8.1% at 12 months

Why this verdict

The stated numerical results match the profile: 9.6% versus 4.3% recurrent weight lost at 6 months and 14.8% versus 8.1% at 12 months.

1

Study evidence

At 6 months, GLP-1 RA users lost a larger proportion of recurrent weight than matched non-users.Mean % recurrent weight lost: 9.6% (GLP-1 RA users) vs. 4.3% (non-users); p = 0.005

“We conducted a retrospective new-user cohort study using OneFlorida+ Data Trust (2015-2024) among adults with ≥ 10% post-MBS weight recurrence.”
Claim 4 of 5SupportedResearchers found no evidence of an increased risk of gastrointestinal or postsurgical complications they evaluated among patients taking the medications.View evidenceHide evidence

Why this verdict

The profile reports that safety outcomes included gastrointestinal and post-MBS adverse events and that Cox models found no increased risk for GLP-1 RA users at either time point. The story appropriately limits the statement to the evaluated complications and uses 'no evidence of an increased risk' rather than claiming definitive safety.

1

Study evidence

GLP-1 RA initiation was not associated with an increased risk of gastrointestinal or post-MBS adverse events at 6 or 12 months compared with matched non-users in this OneFlorida+ retrospective cohort; safety was assessed using Cox proportional hazards models.

“safety outcomes included gastrointestinal and post-MBS adverse events.”
Claim 5 of 5SupportedBecause the study was observational, it cannot establish that the medications caused the differences in weight loss.View evidenceHide evidence

Why this verdict

The paper profile identifies the study as a retrospective observational EHR-based cohort and lists residual confounding as a limitation despite matching and IPTW. The story’s caveat that the study cannot establish causation is consistent with that design.

1

Study evidence

At 6 months, GLP-1 RA users lost a larger proportion of recurrent weight than matched non-users.Mean % recurrent weight lost: 9.6% (GLP-1 RA users) vs. 4.3% (non-users); p = 0.005

“We conducted a retrospective new-user cohort study using OneFlorida+ Data Trust (2015-2024) among adults with ≥ 10% post-MBS weight recurrence.”
2

Study evidence

GLP-1 RA initiation was not associated with an increased risk of gastrointestinal or post-MBS adverse events at 6 or 12 months compared with matched non-users in this OneFlorida+ retrospective cohort; safety was assessed using Cox proportional hazards models.

“safety outcomes included gastrointestinal and post-MBS adverse events.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Population eligibility: adults had at least 10% weight recurrence after metabolic/bariatric surgery.

    The story describes people who regained weight after bariatric surgery but does not reflect the abstract’s ≥10% post-MBS weight-recurrence criterion, which narrows the population to whom the findings apply.

    From Retrospective new-user cohort (EHR/clinical data trust); Retrospective new-user cohort study (OneFlorida+ EHR)

  • Modest sample sizes: 68 GLP-1 RA users and 131 non-users at 6 months; 72 users and 139 non-users at 12 months.

    The story presentation does not mention sample sizes. This is a material precision and generalizability limitation, especially for safety outcomes.

    From Retrospective new-user cohort (EHR/clinical data trust); Retrospective new-user cohort study (OneFlorida+ EHR)

  • Safety reporting limitation: the abstract reports no numerical hazard ratios or confidence intervals for adverse event outcomes.

    The story reports the qualitative safety conclusion but does not mention that the abstract-level safety evidence lacks numerical HRs or confidence intervals, limiting assessment of precision.

    From Retrospective new-user cohort study (OneFlorida+ EHR)

5 things the story did carry across
  • Primary effectiveness finding: GLP-1 RA users with post-bariatric weight recurrence lost a larger percentage of recurrent weight than matched non-users at 6 and 12 months.
  • Primary safety finding: no increased risk of measured gastrointestinal or post-MBS adverse events was detected among GLP-1 RA users compared with non-users.
  • Study design and data source: retrospective new-user observational cohort using OneFlorida+ EHR/clinical data, with matching and inverse probability of treatment weighting.
  • Causal limitation: observational design leaves potential residual confounding despite matching and IPTW.
  • Follow-up was limited to 6- and 12-month outcomes in the abstract; longer-term effectiveness and safety were not reported.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssess real-world effectiveness of GLP-1 receptor agonists for weight recurrence after metabolic/bariatric surgery (recurrent weight loss at 6 and 12 months).Retrospective new-user cohort (EHR/clinical data trust)Expand

In plain English

Retrospective new-user cohort study (OneFlorida+ 2015–2024) comparing adults with ≥10% post-bariatric surgery weight recurrence who initiated GLP-1 receptor agonists versus matched non-users. Primary effectiveness outcome was percentage of recurrent weight lost at 6 and 12 months; analyses used matching, inverse probability of treatment weighting, and t-tests for continuous outcomes. GLP-1 RA users lost a larger share of recurrent weight at 6 months (9.6% vs. 4.3%, p=0.005) and 12 months (14.8% vs. 8.1%, p=0.017). Safety (gastrointestinal and post-MBS adverse events) showed no increased risk in GLP-1 RA users using Cox proportional hazards models.

Key findings

  • At 6 months, GLP-1 RA users lost a larger proportion of recurrent weight than matched non-users.Mean % recurrent weight lost: 9.6% (GLP-1 RA users) vs. 4.3% (non-users); p = 0.005
  • At 12 months, GLP-1 RA users lost a larger proportion of recurrent weight than matched non-users.Mean % recurrent weight lost: 14.8% (GLP-1 RA users) vs. 8.1% (non-users); p = 0.017
“We conducted a retrospective new-user cohort study using OneFlorida+ Data Trust (2015-2024) among adults with ≥ 10% post-MBS weight recurrence.”
What this piece can’t prove
  • Retrospective observational design (EHR data) inherently at risk for residual confounding despite matching and IPTW.
  • Abstract does not report adjusted effect estimates (e.g., adjusted means or confidence intervals) for the continuous weight outcomes, nor hazard ratios/CIs for safety outcomes.

2 further details could not be confirmed from the summary.

2secondary dataAssess real-world safety of GLP-1 receptor agonists in this post-bariatric weight-recurrence population (gastrointestinal and post-MBS adverse events).Retrospective new-user cohort study (OneFlorida+ EHR)Expand

In plain English

In a retrospective new-user cohort of adults with ≥10% weight recurrence after metabolic/bariatric surgery using OneFlorida+ EHR data, initiation of GLP-1 receptor agonists was not associated with an increased risk of gastrointestinal or post-MBS adverse events over 6- and 12-month follow-up when compared with matched non-users; safety was evaluated using Cox proportional hazards models.

Key findings

  • GLP-1 RA initiation was not associated with an increased risk of gastrointestinal or post-MBS adverse events at 6 or 12 months compared with matched non-users in this OneFlorida+ retrospective cohort; safety was assessed using Cox proportional hazards models.
“safety outcomes included gastrointestinal and post-MBS adverse events.”
What this piece can’t prove
  • Retrospective observational design using EHR data (OneFlorida+); potential for misclassification or incomplete capture of adverse events.
  • Abstract does not report numerical effect estimates (HRs), confidence intervals, or statistical test details for safety outcomes.
  • Modest sample sizes at each timepoint may limit precision for detecting differences in adverse event rates.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 33 candidate papers

Candidate

Venous Thromboembolism: Risk Assessment and Prophylaxis

The ASMBS Textbook of Metabolic and Bariatric Surgery · 2026 · Crossref

Source (opens in a new tab)

And 27 more candidates considered.